|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Secginli S: Mammography self-efficacy
scale and breast cancer fear scale: Psychometric testing of the
Turkish versions. Cancer Nurs. 35:365–373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peters JM, Franke WW and Kleinschmidt JA:
Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and
their distribution in the nucleus and the cytoplasm. J Biol Chem.
269:7709–7718. 1994.PubMed/NCBI
|
|
4
|
Tsakiri EN and Trougakos IP: The amazing
ubiquitin-proteasome system: Structural components and implication
in aging. Int Rev Cell Mol Biol. 314:171–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ling Q and Jarvis P: Functions of plastid
protein import and the ubiquitin-proteasome system in plastid
development. Biochim Biophys Acta. 1847:939–948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Csizmar CM, Kim DH and Sachs Z: The role
of the proteasome in AML. Blood Cancer J. 6:e5032016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee GY, Haverty PM, Li L, Kljavin NM,
Bourgon R, Lee J, Stern H, Modrusan Z, Seshagiri S, Zhang Z, et al:
Comparative oncogenomics identifies PSMB4 and SHMT2 as potential
cancer driver genes. Cancer Res. 74:3114–3126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhong J, Shaik S, Wan L, Tron AE, Wang Z,
Sun L, Inuzuka H and Wei W: SCF β-TRCP targets MTSS1 for
ubiquitination-mediated destruction to regulate cancer cell
proliferation and migration. Oncotarget. 4:2339–2353. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim YH, Kim JH, Choi YW, Lim SK, Yim H,
Kang SY, Chung YS, Lee GY and Park TJ: Gankyrin is frequently
overexpressed in breast cancer and is associated with ErbB2
expression. Exp Mol Pathol. 94:360–365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Manasanch EE and Orlowski RZ: Proteasome
inhibitors in cancer therapy. Nat Rev Clin Oncol. 14:417–433. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pellom ST Jr and Shanker A: Development of
proteasome inhibitors as therapeutic drugs. J Clin Cell Immunol.
S5:52012.PubMed/NCBI
|
|
12
|
Nandi D, Woodward E, Ginsburg DB and
Monaco JJ: Intermediates in the formation of mouse 20S proteasomes:
Implications for the assembly of precursor beta subunits. EMBO J.
16:5363–5375. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu R, Lu S, Deng Y, Yang S, He S, Cai J,
Qiang F, Chen C, Zhang W, Zhao S, et al: PSMB4 expression
associates with epithelial ovarian cancer growth and poor
prognosis. Arch Gynecol Obstet. 293:1297–1307. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Liu H, Cui M, Liu J, Yi R, Niu Y,
Chen T and Zhao Y: Effect of the HBV whole-X gene on the expression
of hepatocellular carcinoma associated proteins. J Microbiol
Immunol Infect. 49:335–343. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Valdagni R, Rancati T, Ghilotti M,
Cozzarini C, Vavassori V, Fellin G, Fiorino C, Girelli G, Barra S,
Zaffaroni N, et al: To bleed or not to bleed. A prediction based on
individual gene profiling combined with dose-volume histogram
shapes in prostate cancer patients undergoing three-dimensional
conformal radiation therapy. Int J Radiat Oncol Biol Phys.
74:1431–1440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng-Hao D, Ji-Fang W, De-Sheng X and
Jian-Hua Z: Galectin-1 is up-regulated by RASSF1A gene in human
gastric carcinoma cell line SGC7901. APMIS. 120:582–590. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thaker NG, Zhang F, McDonald PR, Shun TY,
Lewen MD, Pollack IF and Lazo JS: Identification of survival genes
in human glioblastoma cells by small interfering RNA screening. Mol
Pharmacol. 76:1246–1255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng P, Guo H, Li G, Han S, Luo F and Liu
Y: PSMB4 promotes multiple myeloma cell growth by activating
NF-κB-miR-21 signaling. Biochem Biophys Res Commun. 458:328–333.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Runowicz CD, Leach CR, Henry NL, Henry KS,
Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge
SB, Jacobs LA, et al: American Cancer Society/American Society of
Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin
Oncol. 34:611–635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adamczyk A, Niemiec JA, Ambicka A,
Mucha-Małecka A, Mituś J and Ryś J: CD44/CD24 as potential
prognostic markers in node-positive invasive ductal breast cancer
patients treated with adjuvant chemotherapy. J Mol Histol.
45:35–45. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu
JS, Shao ZM, Shen ZZ and Shen KW: Molecular subtype can predict the
response and outcome of Chinese locally advanced breast cancer
patients treated with preoperative therapy. Oncol Rep.
23:1213–1220. 2010.PubMed/NCBI
|
|
22
|
Yao N, Song Z, Wang X, Yang S and Song H:
Prognostic Impact of Progesterone Receptor Status in Chinese
Estrogen Receptor Positive Invasive Breast Cancer Patients. J
Breast Cancer. 20:160–169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirano Y, Kaneko T, Okamoto K, Bai M,
Yashiroda H, Furuyama K, Kato K, Tanaka K and Murata S: Dissecting
beta-ring assembly pathway of the mammalian 20S proteasome. EMBO J.
27:2204–2213. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Poulaki V, Mitsiades CS, Kotoula V, Negri
J, McMillin D, Miller JW and Mitsiades N: The proteasome inhibitor
bortezomib induces apoptosis in human retinoblastoma cell lines in
vitro. Invest Ophthalmol Vis Sci. 48:4706–4719. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yin D, Zhou H, Kumagai T, Liu G, Ong JM,
Black KL and Koeffler HP: Proteasome inhibitor PS-341 causes cell
growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Oncogene. 24:344–354. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fribley A, Zeng Q and Wang CY: Proteasome
inhibitor PS-341 induces apoptosis through induction of endoplasmic
reticulum stress-reactive oxygen species in head and neck squamous
cell carcinoma cells. Mol Cell Biol. 24:9695–9704. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou B, Damrauer JS, Bailey ST, Hadzic T,
Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, et al:
Erythropoietin promotes breast tumorigenesis through
tumor-initiating cell self-renewal. J Clin Invest. 124:553–563.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Templin J, Atanackovic D, Hasche D,
Radhakrishnan SV and Luetkens T: Oscillating expression of
interleukin-16 in multiple myeloma is associated with
proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation.
Oncotarget. 8:49253–49263. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eroles P, Bosch A, Pérez-Fidalgo JA and
Lluch A: Molecular biology in breast cancer: Intrinsic subtypes and
signaling pathways. Cancer Treat Rev. 38:698–707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Abdel-Mageed AB and Agrawal KC: Activation
of nuclear factor kappaB: Potential role in
metallothionein-mediated mitogenic response. Cancer Res.
58:2335–2338. 1998.PubMed/NCBI
|
|
31
|
Biswas DK, Cruz AP, Gansberger E and
Pardee AB: Epidermal growth factor-induced nuclear factor kappa B
activation: A major pathway of cell-cycle progression in
estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci
USA. 97:8542–8547. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Grundler K, Rotter R, Tilley S, Pircher J,
Czermak T, Yakac M, Gaitzsch E, Massberg S, Krötz F, Sohn HY, et
al: The proteasome regulates collagen-induced platelet aggregation
via nuclear-factor-kappa-B (NFĸB) activation. Thromb Res.
148:15–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Di Filippo C, Petronella P, Freda F,
Scorzelli M, Ferretti M, Canonico S, Rossi F and D'Amico M:
Involvement of the ubiquitin-proteasome system in the formation of
experimental postsurgical peritoneal adhesions. Mediators Inflamm.
2012:1947232012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pajonk F and McBride WH: The proteasome in
cancer biology and treatment. Radiat Res. 156:447–459. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ehrlich ES, Chmura JC, Smith JC, Kalu NN
and Hayward GS: KSHV RTA abolishes NFκB responsive gene expression
during lytic reactivation by targeting vFLIP for degradation via
the proteasome. PLoS One. 9:e913592014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kiliccioglu I, Konac E, Varol N, Gurocak S
and Bilen Yucel C: Apoptotic effects of proteasome and histone
deacetylase inhibitors in prostate cancer cell lines. Genet Mol
Res. 13:3721–3731. 2014. View Article : Google Scholar : PubMed/NCBI
|
